What Survodutide is
Investigational dual glucagon/GLP-1 receptor agonist in advanced clinical development for obesity and metabolic liver disease. It is also referred to as BI 456906.
How it works
Combines GLP-1 receptor activity with glucagon-receptor signaling intended to reduce appetite and increase energy/liver-fat metabolism.
What the evidence shows
Phase 2 and ongoing phase 3 development provide substantial human evidence, but the drug remains investigational.
Evidence level: B — Strong human investigational evidence.
Routes studied: Subcutaneous weekly in trials.
Doses studied: Phase 2 trials titrated to 4.8–6.0 mg weekly. That is clinical-trial dosing, not a treatment protocol.
What this page does not claim
Survodutide is investigational and is not available for prescription or compounding.
Safety considerations
GI adverse effects such as nausea, vomiting and diarrhea are common in GLP-1-class development.
- Cautions and contraindications: Trial-specific.
- Possible interactions: Other glucose-lowering agents.
Sport and anti-doping
Likely non-approved substance under sport rules; verify.
Availability at True Heal Wellness
True Heal Wellness does not offer, sell or administer Survodutide. This page exists as an educational reference only.